Global Ivermectin for Human Market Growth 2024-2030

Global Ivermectin for Human Market Growth 2024-2030

Ivermectin is an antiparasitic medication primarily used in veterinary medicine to treat various parasitic infections in animals. It has also been approved for human use in certain circumstances, such as the treatment of specific parasitic infections like onchocerciasis (river blindness) and strongyloidiasis.

The global Ivermectin for Human market size is projected to grow from US$ 53 million in 2023 to US$ 68 million in 2030; it is expected to grow at a CAGR of 3.7% from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the “Ivermectin for Human Industry Forecast” looks at past sales and reviews total world Ivermectin for Human sales in 2023, providing a comprehensive analysis by region and market sector of projected Ivermectin for Human sales for 2024 through 2030. With Ivermectin for Human sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Ivermectin for Human industry.

This Insight Report provides a comprehensive analysis of the global Ivermectin for Human landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Ivermectin for Human portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Ivermectin for Human market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Ivermectin for Human and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Ivermectin for Human.

United States market for Ivermectin for Human is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Ivermectin for Human is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Ivermectin for Human is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Ivermectin for Human players cover Merck, Perrigo Company plc, Arbor Pharms LLC, TARO and Edenbridge Pharms, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Ivermectin for Human market by product type, application, key manufacturers and key regions and countries.

Segmentation by type
Topical (Cream and Lotion)
Oral
Injection

Segmentation by application
For Onchocerciasis Treatment
For Headlice Treatment
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Merck
Perrigo Company plc
Arbor Pharms LLC
TARO
Edenbridge Pharms
TEVA Pharms USA
Wellona Pharma
Galderma Laboratories LP

Key Questions Addressed in this Report

What is the 10-year outlook for the global Ivermectin for Human market?

What factors are driving Ivermectin for Human market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Ivermectin for Human market opportunities vary by end market size?

How does Ivermectin for Human break out type, application?

Please note: The report will take approximately 2 business days to prepare and deliver.